The role of gemcitabine in the treatment of other tumours

British Journal of Cancer

Volumn 78, Issue SUPPL. 1, 1998, Pages 21-25

  Carmichael, J ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Bladder; Breast; Gemcitabine; Ovary; Solid tumour

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; EPIRUBICIN; GEMCITABINE; NAVELBINE; NUCLEOSIDE ANALOG; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLON CANCER; CONFERENCE PAPER; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; UTERINE CERVIX CANCER;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS; DEOXYCYTIDINE; FEMALE; HUMANS; NEOPLASMS;

EID: 0031824267     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.750     Document Type: Article

References (37)

1. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W and Raber MN (1991) A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 10: 406-441
2. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D and Rugg TA (1994) Efficacy and safety profile of gemcitabine in non-small-cell lung cancer. J Clin Oncol 12: 1535-1540
3. Abratt RP, Bezwoda WR, Goedhals L and Hacking DJ (1997) Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 15: 744-749
4. Anderson H, Lund B, Bach F, Thatcher N, Walling J and Hansen HH (1994) Single agent activity of weekly gemcitabine in advanced non-small cell lung cancer. J Clin Oncol 12: 1821-1826
5. Blackstein M, Vogel CL, Ambinder R, Cowan J, Pearce P, Iglesias J and Dorr FA (1996) Phase II study of gemcitabine in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 15: 117
6. Braakhuis BJM, van Dongen GAMS, Vermorken JB and Snow G (1991) Preclinical in vivo activity of 2′,2′-difluorodeoxycytidine (gemcitabine) against human head and neck cancer. Cancer Res 51: 211-214
7. Burris (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413
8. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B and Tarassoff PG (1994) Phase II trial of gemcitabine (2′,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12: 29-34
9. Carmichael J and Walling J (1996) Phase II activity of gemcitabine in advanced breast cancer. Semin Oncol 23: 77-81
10. Carmichael J, Possinger K, Philip P, Beykirch M, Kerr, H, Walling J and Harris A (1995) Advanced breast cancer: a phase II trial with Gemcitabine. J Clin Oncol 13: 2731-2736
11. Carmichael J, Fink U, Russell RCG, Spittle MF, Harris AL, Spiessi G and Blatter J (1996a) Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73: 101-105
12. Carmichael J, Allerheiligen S and Walling J (1996b) A phase I study of gemcitabine and carboplatin in non-small-cell lung cancer. Semin Oncol 23: 55-59
13. Catimel G, Vermorken JB, Clavel M, de Mulder P, Judson I, Sessa C, Piccart M, Bruntsch U, Verweij J, Wanders J, Franklin H and Kaye SB (1994) A phase II study of gemcitabine (LY L88011) in patients with advanced squamous cell carcinoma of the heart and neck. Ann Oncol 5/6: 543-547
14. Cormier Y, Eisenhauer E, Muldal A, Gregg R, Ayoub J, Goss G, Stewart D, Tarasoff P and Wong D (1994) Gemcitabine is an active new agent in previously untreated, extensive small cell lung cancer - a study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 5: 283-285
15. Crinò L, Scagliotti G, Marangolo M, Figoli F, Clerici M, De Marinis F, Salvati F, Cruciani G, Dogliotti L, Pucci F, Paccagnella A, Adamo V, Altavilla G, Incoronato P, Trippetti M, Mosconi AM, Santucci A, Sorbolini S, Oliva C and Tonato M (1997) Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 15: 297-303
16. De Lena M, Gridelli C, Lorusso V, Amadori D, Antimi M, Luporini G, Pollera C and Oliva C (1996) Gemcitabine activity (objective responses and symptom improvement) in resistant stage IV bladder cancer. Proc Am Soc Clin Oncol 15: 246
17. De Mulder PHM, Weissbach L, Jakse G, Osieka R and Blatter J (1996) Cancer Chemother Pharmacol 37: 491-495
18. Garcia-Conde J, Lluch A, Pérez-Manga G, Palomero I, Alba E, Rueda A, Moreno Noguiera JA, Calvo E, Tarazona Y and López-Martin E (1997) Gemcitabine + doxorubicin in advanced breast cancer: final results from an early phase II study. Proc Am Soc Clin Oncol 16: 147a
19. Gatzemeier U, Shepherd FA, Le Chevalier T, Weynants P, Cottier B, Groen HJM, Rosso R, Mattson K, Cortes-Funes H, Tonato M, Burkes RL, Gottfried M and Voi M (1996) Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 32A: 243-248
20. Goedhals L and Bezwoda WR (1996) A phase II study of gemcitabine in advanced cervix carcinoma: final data. Proc Am Soc Clin Oncol 15: 296
21. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB and Plunkett W (1990) Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 38: 567-572
22. Huang P, Chubb S, Hertel LW, Grindey GB and Plunkett W (1991) Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51: 6110-6117
23. Kaye SB (1994) Gemcitabine - current status of phase I and phase II trials. J Clin Oncol 12: 1527-1531
24. Luftner D, Grunewald R, Flath B, Akrivakis C, Mergenthaler H-G, Blatter J and Possinger K (1996) Gemcitabine with dose escalated epirubicin in advanced breast cancer: results of a phase I study. Ann Oncol 7: 17
25. Lund B, Hansen OP, Theilade K, Hansen M and Neijt JP (1994) Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously untreated ovarian cancer patients. J Natl Cancer Inst 86: 1530-1533
26. Mertens WC, Eisenhauer EA, Moore M, Venner P, Stewart D, Muldal A and Wong D (1993) Gemcitabine in advanced renal cell carcinoma. Ann Oncol 4: 331-332
27. Moore MJ, Tannock I, Ernst S, Huan S and Murray N (1996) Gemcitabine demonstrates promising activity as a single agent in the treatment of metastatic transitional cell carcinoma. Proc Am Soc Clin Oncol 15: 250
28. Neijt JP, Kaufman M, Bauknecht T, van Belle S, Jonat W, Piccart MJ, Thomas J, Wils JAMJ, Nooy MA and Grul CM (1996) Gemcitabine in pretreated ovarian cancer. Ann Oncol 7(suppl. 5): 70
29. Plunkett W, Gandhi V, Chubb S, Nowak B, Heinemann V, Mineishi S, Sen A, Hertel LW and Grindey GB (1989) 2′,2′-Difluorodeoxycytidine metabolism and mechanism of action in human leukaemia cells. Nucleosides Nucleotides 8: 775-785
30. Pollera CF, Ceribelli A, Crecco M and Calabresi F (1994) Weekly gemcitabine in advanced bladder cancer - a preliminary report from a phase I study. Ann Oncol 5: 182-184
31. Shapiro JD, Millward MJ, Rischin D, Michael M, Walcher V, Francis PA and Toner GC (1996) Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynaecol Oncol 63: 89-93
32. Spielmann M, Pouillart P, Espie M, Llombart-Cussac A, Namer M, Kalla S, Ferrero JM, Cuvier C, Fumoleau P, Ponzio A and Kayitalire L (1996) Activity of gemcitabine in metastatic breast cancer. Patients previously treated with anthracycline-containing regimens. Ann Oncol 7(suppl. 5): 23
33. Stadler WM, Kuzel TM, Ragahavan D, Roth B, Vogelzang NJ, Levine EL and Dorr FA (1996) A phase II study of gemcitabine in bladder cancer. Ann Oncol 7: 58
34. Stadler WM, Murphy B, Kaufman D, Raghaven D, Carducci M and Voi M (1997) Phase II trial of gemcitabine plus cisplatin in metastic urothelial cancer. Proc Am Soc Clin Oncol 16: 323a
35. Underhill C, Parnis FX, Highley M, Ahern J, Lund B, Kamby C, Carmichael J, Harper P, Williams C, Hirsch F, Hansen M, Smith C and Walling J (1996) A phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer. Ann Oncol 7(suppl. 5): 69
36. von der Maase H, Andersen L, Crinò L, Weissbach L and Dogliotti L (1997) A phase II study of gemcitabine and cisplatin in patients with transitional cell carcinoma (TCC) of the urothelium. Proc Am Soc Clin Oncol 16: 324a
37. Von Hoff D (1996) Gemcitabine: a case study for clinical benefit. Semin Oncol 23: 1-3